Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease

J. D. Joseph, B. M. Wittmann, M. A. Dwyer, H. Cui, D. A. Dye, D. P. McDonnell, J. D. Norris, Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists Proceedings of the National Academy of Sciences of the United States of America. ,vol. 106, pp. 12178- 12183 ,(2009) , 10.1073/PNAS.0900185106

Hiroko Masuda, Keith A. Baggerly, Ying Wang, Ya Zhang, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam, Vicente Valero, Brian D. Lehmann, Jennifer A. Pietenpol, Gabriel N. Hortobagyi, W. Fraser Symmans, Naoto T. Ueno, Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes Clinical Cancer Research. ,vol. 19, pp. 5533- 5540 ,(2013) , 10.1158/1078-0432.CCR-13-0799

John F.R. Robertson, Antonio Llombart-Cussac, Janusz Rolski, David Feltl, John Dewar, Euan Macpherson, Justin Lindemann, Matthew J. Ellis, Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study Journal of Clinical Oncology. ,vol. 27, pp. 4530- 4535 ,(2009) , 10.1200/JCO.2008.21.1136

Joseph P Garay, Bedri Karakas, Abde M Abukhdeir, David P Cosgrove, John P Gustin, Michaela J Higgins, Hiroyuki Konishi, Yuko Konishi, Josh Lauring, Morassa Mohseni, Grace M Wang, Danijela Jelovac, Ashani Weeraratna, Cheryl A Sherman Baust, Patrice J Morin, Antoun Toubaji, Alan Meeker, Angelo M De Marzo, Gloria Lewis, Andrea Subhawong, Pedram Argani, Ben H Park, The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation Breast Cancer Research. ,vol. 14, pp. 1- 17 ,(2012) , 10.1186/BCR3112

Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard, Wedad M. Hanna, Harriet K. Kahn, Carol A. Sawka, Lavina A. Lickley, Ellen Rawlinson, Ping Sun, Steven A. Narod, Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence Clinical Cancer Research. ,vol. 13, pp. 4429- 4434 ,(2007) , 10.1158/1078-0432.CCR-06-3045

J. Cortes Castan, P. Schmid, A. Awada, H. Uppal, I.C. Tudor, M.E. Blaney, J.L. Steinberg, D.A. Yardley, C. Hudis, T.A. Traina, 13PStage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) Annals of Oncology. ,vol. 26, ,(2015) , 10.1093/ANNONC/MDV115.01

Tiffany A. Traina, Kathy Miller, Denise A. Yardley, Joyce O'Shaughnessy, Javier Cortes, Ahmad Awada, Catherine Margaret Kelly, Maureen E. Trudeau, Peter Schmid, Luca Gianni, Laura García-Estevez, Rita Nanda, Foluso Olabisi Ademuyiwa, Stephen Chan, Joyce Leta Steinberg, Martha Elizabeth Blaney, Iulia Cristina Tudor, Hirdesh Uppal, Amy C. Peterson, Clifford A. Hudis, Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Journal of Clinical Oncology. ,vol. 33, pp. 1003- 1003 ,(2015) , 10.1200/JCO.2015.33.15_SUPPL.1003

Isabelle Ahrens-Fath, Oliver Politz, Christoph Geserick, Bernard Haendler, Androgen receptor function is modulated by the tissue-specific AR45 variant: Androgen receptor variant form FEBS Journal. ,vol. 272, pp. 74- 84 ,(2004) , 10.1111/J.1432-1033.2004.04395.X

Damoun Safarpour, Fattaneh A Tavassoli, Shabnam Pakneshan, Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? American Journal of Cancer Research. ,vol. 4, pp. 353- 368 ,(2014)

Tiffany A Traina, Ayca Gucalp, William Polkinghorn, Steven Isakoff, Sara Tolaney, Lisa Carey, James Ingle, Lisle Nabell, Andres Forero, Hope Rugo, Kimberly Blackwell, Minetta Liu, Matthew Soloway, Lisle Mose, Dilip Giri, Agnes Viale, Clifford Hudis, Charles Sawyers, Joel Parker, None, Abstract P3-04-01: Whole transcriptome analysis of AR+ ER/PR- metastatic breast cancers treated with bicalutamide on TBCRC011 Cancer Research. ,vol. 75, ,(2015) , 10.1158/1538-7445.SABCS14-P3-04-01